Reflections on early stopping of a clinical trial

American Heart Journal

Volumn 152, Issue 3, 2006, Pages 407-409

  Armstrong, Paul W ^a   Granger, Christopher B ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MONOCLONAL ANTIBODY; PEXELIZUMAB;

CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS SURGERY; DRUG SAFETY; EDITORIAL; ELECTROCARDIOGRAM; FOOD AND DRUG ADMINISTRATION; HEART DEATH; HEART INFARCTION; HUMAN; MORBIDITY; MORTALITY; PATIENT CARE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PUBLIC HEALTH; ST SEGMENT ELEVATION;

CARDIOVASCULAR DISEASES; DRUG INDUSTRY; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33747322166     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.06.006     Document Type: Editorial

References (10)

1. DeAngelis C.D., Drazen J.M., Frizelle F.A., et al. Clinical trial registration-a statement from the International Committee of Medical Journal Editors. JAMA 292 (2004) 1363-1364
2. Topol E.J. Arthritis medicines and cardiovascular events-"House of Coxibs". JAMA 293 (2005) 366-368
3. Lievre M., Menard J., Bruckert E., et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety or feasibility. BMJ 322 (2001) 603-605
4. Illtis A.S. Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass. J Med Ethics 31 (2005) 410-414
5. Psaty B.M., and Drummond R. Stopping medical research to save money-a broken pact with researchers and patients. JAMA 289 (2003) 2128-2130
6. Armstrong P.W., Adams P.X., Al-Khalidi H.R., et al., on behalf of the APEX-AMI Steering Committee. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI). A multicenter, randomized, double-blind parallel-group placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J 149 (2005) 402-407
7. Press release-Alexion reports phase III results for PRIMO-CABG2 study. http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104andSTORY=/www/story /11-23-2005/0004222006&EDATE (accessed May 2006)
8. Mahaffey K, Van de Werf F, Shernan S, et al. Effect of pexelizumab on mortality in patients with acute myocardial infarction or undergoing coronary artery bypass surgery: a systematic overview. AHJ (In press).
9. Black H.R., Elliott W.J., Grandits G., et al., for the CONVINCE Research Group. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. JAMA 289 (2003) 2073-2082
10. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682